Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Chronic Coronary Syndrome (CCS)

Published: 03 October 2022

  • Views:

    Views Icon 24687
  • Likes:

    Heart Icon 7
  • episode_image
    9m 52s
    Part 5 Q&A and Discussion
    Philippe Gabriel Steg, Marc P Bonaca, Eva Prescott, Deepak L Bhatt
Average (ratings)
No ratings
Your rating

Overview

This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?' will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.

 

The second broadcast in this series, focused on Chronic Coronary Syndrome (CCS). In this on-demand version of the live broadcast, Radcliffe Medical Education brings together a global faculty of experts in the field to look at current guidance, the landmark data, gaps in evidence and seeks to provide practical guidance.

 

Prof Philippe Gabriel Steg (Hospital Bichat-Claude Bernard, FR) chairs the proceedings, and is joined by Dr Marc Bonaca (University of Colorado School of Medicine, US) and Dr Deepak Bhatt (Brigham and Women's Hospital, US) for a series of insightful presentations and discussions.

 

Catch up now on the other broadcasts in this series:

This broadcast series is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

Following the completion of this programme, physicians will be in a position to:

  • Discuss the disease burden in both primary and secondary prevention patients with high-risk features
  • Identify clinical features that make CCS patients high risk
  • Choose an appropriate antiplatelet regimen for CCS patients based on relevant history and current risk profile
  • Recall the results of RCTs using potent P2Y12 inhibitors in CCS patients with a prior MI and in patients with existing diabetes, with/without MI

Target Audience

  • General Cardiologists
  • Interventional Cardiologists
  • Nurses and any other allied HCPs

More from this programme

Part 1

Unmet Needs in CCS

In this first part, Dr Marc Bonaca discusses the current unmet needs in Chronic Coronary Syndrome.

Part 2

Risk Mitigation in High and Very High-Risk Patients: What Does the Data Say?

Prof Philippe Gabriel Steg looks at the data behind risk mitigation in high and very high-risk patients.

Part 3

Prevention in Diabetes

Dr Deepak Bhatt discusses primary and secondary prevention in patients with type 2 diabetes.

Part 4

Long-term Management of CCS

Dr Marc Bonaca discusses how to apply the evidence to practice looking at the long-term management of CCS.

Part 5

Q&A and Discussion

In this final chapter, Prof Philippe Gabriel Steg addresses questions received by the audience to our panel.

Faculty Biographies

Deepak L Bhatt

Deepak L Bhatt

Executive Director of Interventional Cardiovascular Programs

Dr Deepak Bhatt is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School.

Dr Bhatt has more than 1,600 publications and has been listed by the Web of Science as a Highly Cited Researcher.

He is Editor of the peer-reviewed Journal of Invasive Cardiology and Editor-in-Chief of the Harvard Heart Letter for patients. He received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, and AHA’s Distinguished Scientist Award in 2019.

View full profile